Serum metabolomic signatures predict clinical outcomes in advanced non-small cell lung cancer treated with pembrolizumab plus platinum-based chemotherapy - Poll - MDSpire

Serum metabolomic signatures predict clinical outcomes in advanced non-small cell lung cancer treated with pembrolizumab plus platinum-based chemotherapy

  • By

  • Peter May

  • Christof Winter

  • Inga Hubrecht

  • Adrian Patenge

  • Selina Strathmeyer

  • Roland Geyer

  • Steffen Heelemann

  • Jan Stratmann

  • Seyer Safi

  • Henriette Klein

  • Folker Schneller

  • Florian Bassermann

  • Aaron Becker von Rose

  • May 18, 2026

  • 0 min

Share

Original Source(s)

Serum metabolomic signatures predict clinical outcomes in advanced non-small cell lung cancer treated with pembrolizumab plus platinum-based chemotherapy

  • by Peter May, Christof Winter, Inga Hubrecht, Adrian Patenge, Selina Strathmeyer, Roland Geyer, Steffen Heelemann, Jan Stratmann, Seyer Safi, Henriette Klein, Folker Schneller, Florian Bassermann, Aaron Becker von Rose

  • May 18, 2026

Related Content

Case report and literature review: the effect of surgical management in intrathoracic pseudomyxoma peritonei

Papillary thyroid carcinoma with brain and lung metastases: a case report

Tumor irradiation promotes antigen dressing of dendritic cells to enhance CAR T cell persistence and efficacy in lung metastases